Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escitalopram for Agitation in Alzheimer's Disease

Trial Profile

Escitalopram for Agitation in Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms S-CitAD
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 1 Mar 2021 to 1 Aug 2022.
    • 08 Jun 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
    • 11 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top